To include your compound in the COVID-19 Resource Center, submit it here.

Humacyte completes enrollment in Phase III of Humacyl for ESRD

Humacyte Inc. (Research Triangle Park, N.C.) completed enrollment of 350 evaluable patients with end-stage renal disease (ESRD)

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE